Replies to post #109530 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

now, a blockbuster announcement, like a grant would change everything. Its been two years since the company reported on the last study that got a grant, And so it is almost three years since they got their last grant.

Publish or perish. And if you can't find anything good to publish, it severely hurts your credibility. They would not be continuing with this Lympro study if the number of patients studied to date made a difference.

Finally, using any evaluation method, Lympro Ad v healthy controls has never been in the 90s sen and spec, so I am not holding my breath on better results.

JN is certainly free to report that the company expects better results, but that is not offering a sentient opinion. Do the same thing and expecting better results is not a healthy way to proceed.